中国医药健康产业股份有限公司第十届董事会第1次会议决议公告

Meeting Overview - The first meeting of the 10th Board of Directors of China National Pharmaceutical Group Co., Ltd. was held on February 9, 2026, combining in-person and communication methods [2] - All 8 directors attended the meeting, and the meeting complied with the relevant provisions of the Company Law and Articles of Association, making the resolutions valid [4][5] Resolutions Passed - The board elected Mr. Yang Guang as the Chairman and legal representative of the company, with a term from the date of approval until the end of the 10th Board's term [6] - The board approved the election of members for various specialized committees, including: - Strategy and ESG Committee: Mr. Yang Guang (Chairman), Mr. Pan Zhen, Mr. Li Zhiyong, Mr. Fan Xiongtao - Audit and Risk Control Committee: Mr. Wang Ruihua (Chairman), Ms. Yan Yonghong, Mr. Fan Xiongtao - Nomination Committee: Ms. Yan Yonghong (Chairman), Mr. Wang Ruihua, Mr. Yang Guang - Compensation and Assessment Committee: Mr. Li Zhiyong (Chairman), Mr. Wang Ruihua, Ms. Sun Zhuo [8][10] - The board appointed Mr. Yang Guang as the General Manager, with a term from the date of approval until the end of the 10th Board's term [12] - The board approved the appointment of senior management personnel, including: - Mr. Zhang Peng and Mr. Chen Jianxiong as Vice General Managers - Ms. Ge Xiaohong as Chief Accountant - Mr. Zhang Huibo and Mr. Lü Heping as Assistant General Managers - Mr. Zhang Jian as Chief Legal Advisor [14][15] - The board appointed Mr. Yuan Jinghua as the Secretary of the Board and Ms. Guo Fan as the Securities Affairs Representative [17][19] - The board approved the renewal of the office lease for the General Times Center for one year, with a total rental amount not exceeding 62.2451 million yuan (including tax) [21][37] Office Lease Details - The lease agreement is with China General Technology (Group) Holding Limited and its property management company, covering the period from January 1, 2026, to December 31, 2026 [37] - The total rental and property service fees are expected to be no more than 72.1593 million yuan [37] - The rental price remains unchanged compared to 2025, based on market pricing and surrounding office buildings [39][52] New Drug Registration - The company’s subsidiary, Tianfang Pharmaceutical Co., Ltd., received two drug registration certificates for fumaric acid volnoreline tablets from the National Medical Products Administration [64] - The drug is primarily used for treating reflux esophagitis and eradicating Helicobacter pylori when used with appropriate antibiotics [65] - The total investment in the drug's raw materials and formulation projects is approximately 12.32 million yuan [67] - The market for this drug is projected to have sales of approximately 774 million yuan in 2024 and 778 million yuan in the first three quarters of 2025 [68]